Clinical Trials Directory

We are doing this study to find out if a study drug called belzupacap sarotalocan (bel-sar) is a safe and effective option when it is combined with laser light therapy for people who have a type of eye cancer called an indeterminate lesion (a growth in your eye that is suspected to be melanoma) or choroidal melanoma, which is also known as eye melanoma.

We are doing this study to compare 2 different regimens for treating pancreatic cancer after surgery. We what find out how well patients do after they get a combination of the drugs cevumeran, atezolizumab, and mFOLFIRINOX compared to just getting mFOLFIRINOX alone. Cevumeran is an experimental drug that is made from your own cells that are obtained from blood and tissue samples. It is designed to activate your immune system against cancer cells in your body.

We are doing this study to find out if a drug called durvalumab (the study drug) is a safe and effective option for patients with resectable or borderline resectable (Stage IIB to IIIB) NSCLC. We will compare how well the study drug works versus the usual treatment for this type of cancer. Durvalumab is approved for the treatment of advanced NSCLC after chemotherapy and radiation, but it is still considered experimental for less advanced forms of NSCLC.

We are doing this study promote the importance of quitting smoking for pregnant women and to improve how providers can help their patients quit smoking.

We are doing this study to find out if pictures taken of the back of the eye (retina) using a special type of camera called Optical Coherence Tomography (OCT) can predict how well a baby will be able to see and how their brain works at school age. El propósito de este estudio es determinar si las fotos tomadas del fondo de ojo (retina) usando una cámara especial que se llama Tomografía de coherencia Óptica (OCT), puede predecir la visión y como el cerebro funciona a la edad escolar.

We are doing this study to compare the outcomes of 2 treatments for women with stress urinary incontinence (SUI): transurethral bulking agent (TBA) and single-incision sling (SIS). Both treatments are FDA-approved and can help improve SUI symptoms, but they have not been directly compared to each other to see which treatment is better for certain patients and under what circumstances. We hope this study can help women and their doctors find out which option is most likely to have the best results. Current evidence suggests that TBA and SIS are less effective than a traditional full-length mid-urethral sling procedure, but both options are less invasive and less likely to cause complications afterward.

We are doing this study to find out if an investigational drug called TP-3654 (the study drug) is a safe and effective treatment for myelofibrosis. The study drug will be tested at different doses to find out what effects, if any, it has on myelofibrosis.

We are doing this study to find the most effective, safe dose of an experimental drug called ficerafusp alfa (BCA101 - the study drug) when it is given in combination with pembrolizumab for people who have metastatic/recurrent head and neck squamous cell carcinoma (HNSCC).